Transforming Pharmaceutical Manufacturing with the PLI Scheme in India
Sunday, 16 March 2025, 16:30
Boosting Domestic Drug Production through the PLI Scheme
India is enhancing its pharmaceutical manufacturing capabilities significantly. The PLI scheme encourages the production of essential bulk drugs, specifically active pharmaceutical ingredients (APIs) like penicillin G and clavulanic acid. This initiative plays a crucial role in minimizing drug imports and promoting self-sufficiency in drug exports.
Key Beneficiaries of the PLI Scheme
- Paracetamol - an essential analgesic
- Atorvastatin - critical for managing cholesterol levels
- Biopharmaceuticals for treating non-communicable diseases
The push for domestic manufacturing under this scheme is vital in ensuring a sustainable supply chain and enhancing the overall resilience of India's pharmaceutical industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.